Steve Harr has been busy.
Over the past 9 months or so, the former Juno CFO who helped break ground on CAR-T tech has been creating a new biotech called Sana Biotechnology with some big goals in mind.
Sana is jumping from stage right into what it hopes will be the center ring of next-gen technology aimed at creating a new wave of cell and gene therapies that can be used off-the-shelf to go where needed to fix a variety of diseases — unbound by disease fields or even hub boundaries.
“We want to build something that is epic in its impact on patients,” says the CEO. Epic and enduring.
Harr isn’t talking money right now — “you can make your own conjectures" — but his 3 current backers tell me that money isn’t an issue.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription